TG THERAPEUTICS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+78.0% +$84M
$193M
Cost of Revenue↑+147.7% +$23M
$38M
R&D↑+72.5% +$17M
$41M
SG&A↑+61.0% +$24M
$63M
D&A↑+133.3% +$12K
$21K
Operating Income↑+71.2% +$21M
$50M
EBITDA↑+71.2% +$21M
$51M
Interest Expense↓-7.5% -$528K
$7M
Other Income/Expense↑+202.2% +$2M
$1M
Pretax Income↑+111.4% +$24M
$45M
Tax Provision↑+1109.9% +$20M
$22M
Net Income↑+18.1% +$4M
$23M
Operating Margin↓-1.0pts
26.2%
Net Margin↓-6.1pts
12.0%
Effective Tax Rate↑+40.4pts
48.9%
Deferred Tax Assets
$367M
ETR (Continuing Operations)
-316.4%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
-6.0%
Operating Lease Cost↓-25.6% -$153K
$445K
Revenue YoY Variation↓-68.0pts
78.0%
Income YoY Variation
71.2%
Revenue QoQ Variation↓-9.9pts
19.1%
Income QoQ Variation↓-65.3pts
72.0%